In melanoma, the biopsies are assessed routinely for the density of various cell types in the TME, like CD8+ tumor-infiltrating lymphocytes, NK cells, B cells, histiocytes, and fibroblasts, to monitor their changes in subsequent biopsies for tumor progression or response to therapy [13]. The gene discussed is CD8A; the disease is melanoma.